Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285Aexternal-prioritypatent/CU23000A1/en
Application filed by Centro Inmunologia MolecularfiledCriticalCentro Inmunologia Molecular
Publication of MY129626ApublicationCriticalpatent/MY129626A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
THIS INVENTION DISCLOSES MEANS FOR OBTAINING IMMUNOGENIC PEPTIDES, POLYPEPTIDES, PROTEINS, AND THEIR CORRESPONDING NUCLEIC ACID SEQUENCES, TARGET CELLS WITH VACCINE INTEREST , OR LYSATES THEREOF, WITHOUT MAKING STRUCTURAL CHANGES IN SAID ANTIGENS, THROUGH THEIR ASSOCIATION WITH VERY SMALL SIZE PROTEOLIPOSEMES.THE OBJECT OF THE INVENTION IS TO PROVIDE IMMUNOGENIC COMPOSITIONS CONTAINING PEPTIDES, POLYPEPTIDES, PROTEINS, THEIR CORRESPONDING DNA SEQUENCES, CELLS OR THEIR LYSATES AND VERY SMALL SIZE PROTEOLIPOSOMES (VSSP), WHICH ARE FORMED BY BINDING THE OUTER MEMBRANE PROTEIN COMPLEX (OMPC) OF NEISSERIA MENINGITIDIS WITH GANGLIOSIDES, BY MEANS OF HYDROPHOBIC LINK. ADDITIONALLY, IT IS STATED THAT COMPOSITIONS CAN BE FORMULATED ALONE OR IN THE FORM OF EMULSIONS WITH THE INCOMPLETE FREUND'S ADJUVANT (IFA), AND MAY ALSO BE IYOPHILIZED.THE ESSENCE OF THE INVENTION CONSISTS IN DESCRIBING COMPOSITIONS THAT TRIGGERS IMMUNOGENICIY IN LOW IMMUNOGENIC ANTIGENS, SUCH AS GROWTH FACTOR RECEPTORS, WITHOUT IMPARTING STRUCTURAL CHANGES THEREIN. PARTICULARLY, THIS INVENTION REFERS TO PREPARATION OF IMMUNO-STIMULATING COMPOSITIONS CAPABLE OF GENERATING ANTIGEN-SPECIFIC RESPONSES, EVEN IN IMMUNO-COMPROMISED HOST, SUCH AS THOSE SUFFERING FORM CANCER OR VIRAL OR BACTERIAL CHRONIC INFECTIONS. IN SAID PETIENTS, THE ADMINISTRATION OF THE VACCINE COMPOSITIONS DESCRIBED IN THIS INVENTION HAS LEAD TO THE REESTABLISHMENT OF THE FUNCTIONALITY OF THE IMMUNE SYSTEM.VACCINE COMPOSITIONS OF THIS INVENTION CAN BE USED TO PROTECT OR TREAT INFECTIONS, OR AUTO-IMMUNE DISEASES.
MYPI200155582000-12-062001-12-05Preparations that potentiate immunogenicity in low immunogenic antigens
MY129626A
(en)
Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP
Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine